← Back to Search

Behavioral Intervention

Nudge for Ovarian Cancer

N/A
Waitlist Available
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adnexal mass identified on imaging (i.e., O-RADS 4 or 5 on ultrasound or MRI, Codex 4 or 5 on CT) ordered by Penn Medicine clinician
Be older than 18 years old
Must not have
Known diagnosis of ovarian cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 365 days
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to improve outcomes for ovarian cancer patients by ensuring they see a gynecologic oncologist promptly after diagnosis. Currently, many patients do not see a specialist, leading to delays in treatment,

Who is the study for?
This trial is for individuals diagnosed with ovarian cancer, peritoneal neoplasm, or fallopian tube cancer. It aims to improve the referral rate to gynecologic oncology specialists at diagnosis. The study focuses on patients who have not yet seen a gynecologic oncologist.
What is being tested?
The trial is testing a 'nudge' strategy to increase referrals of newly diagnosed patients to gynecologic oncologists. Its effectiveness will be measured against past data where no such nudge was applied.
What are the potential side effects?
Since this intervention involves a referral process rather than medication or surgery, there are no direct medical side effects associated with the nudge itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My scan shows a significant ovarian mass.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with ovarian cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~365 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 365 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adoption
Secondary study objectives
Adherence to Treatment
Gyn Onc Visits
Progression Free and Overall Survival

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: NudgeExperimental Treatment1 Intervention
The study consists of one intervention, a clinician nudge to gynecologic oncology referral.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nudge
2022
N/A
~56380

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor
418 Previous Clinical Trials
464,832 Total Patients Enrolled
~10 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top